NCT05150340 - A Study of TAK-771 in Japanese People With Primary Immunodeficiency Diseases (PID) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 24, 2022

Primary Completion Date

August 28, 2023

Study Completion Date

August 28, 2023

Conditions

Primary Immunodeficiency Diseases (PID)

Interventions

DRUG

TAK-771

Intervention description; Immune Globulin Infusion (IGI) 10% and Recombinant Human Hyaluronidase (rHuPH20)

Trial Locations (12)

Nagoya University Hospital, Nagoya

Hospital of University of Occupational and Environmental Health, Kitakyushu

Kurume University Hospital, Kurume

Kanagawa Children's Medical Center, Yokohama

Shinshu University Hospital, Matsumoto

Tokyo Medical Dental University Hospital, Bunkyo-ku

National Center for Child Health and development, Setagaya-ku

Kyushu University Hospital, Fukuoka

Gifu University Hospital, Gifu

Hiroshima University Hospital, Hiroshima

Saitama Prefectual Children's Medical Center, Saitama

Shizuoka Childrens Hospital, Shizuoka